Percheron Therapeutics raises $2.2 million as HMBD-002 phase II preparations advance

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) progressed preparations for a planned phase II clinical trial of HMBD-002, its lead oncology program, during...